[原著・総説]

• Nakabayashi M, Osaki M, Kodani I, Okada F, Ryoke K, Oshimura M, Ito H and Kugoh H. PITX1 is reliable biomarker for predicting prognosis in patients with oral epithelial dysplasia. Oncol Lett  7: 750-754, 2014.
  

• Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F and Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol  44 (1): 53-58, 2014. 
  

           【 International Journal of Oncology誌に於いて，2014年に最も

               引用された論文として紹介されました】

• Shimamoto A, Kagawa H, Zensho K, Sera Y, Kazuki Y, Osaki M, Oshimura M, Ishigaki Y, Hamasaki K, Kodama Y, Yuasa S, Fukuda K, Hirashima K, Seimiya H, Koyama H, Shimizu T, Takemoto M, Yokote K, Goto M and Tahara H. Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. PLoS One 9 (11): e112900, 2014. 
  

• Kazuki Y, Yakura Y, Abe S, Osaki M, Kajitani N, Kazuki K, Takehara S, Honma K, Suemori H, Yamazaki S, Sakuma T, Toki T, Shimizu R, Nakauchi H, Yamamoto T and Oshimura M. Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies Sci Rep 4: 6136, 2014.
  

• Okada F. Inflammation-related carcinogenesis: Current findings in epidemiological trends, causes and mechanisms. Yonago Acta Med 57: 65-72, 2014.
  

• Kanda Y, Kawaguchi T, Kuramitsu Y, Kitagawa T, Kobayashi T, Takahashi N, Tazawa H, Habelhah H, Hamada J-I, Kobayashi M, Hirahata M, Onuma K, Osaki M, Nakamura K, Kitagawa T, Hosokawa M and Okada F. Fascin regulates chronic inflammation-related human colon carcinogenesis by inhibiting cell anoikis. Proteomics 14 (9): 1031-1041, 2014.
  

• Wang Y, Kuramitsu Y, Tokuda K, Okada F, Baron B, Akada J, Kitagawa T, Nakamura K. Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma. Electrophoresis 2014 in press.
  

• Osaki M, Kosaka N, Okada F, Ochiya T. Circulating miRNAs in drug safety assessment for hepatic and cardiovascular toxicity: the latest biomarker frontier? Mol Diagn Ther 18 (2): 121-126, 2014.